Daniel Shvartsman

Long only, value
Daniel Shvartsman
Long only, value
Contributor since: 2012
6/23/12
Daniel Shvartsman
$TEVA wins Copaxone trial, up almost 7% ACHI. I'm bummed it never dropped to my limit orders at 37.5. Weird to drop good news late on Friday.
Hopefully it'll continue up a bit, looking to lighten up my position.
5/11/12
Daniel Shvartsman
For those worried about $JPM, needing safer financial plays, I wrote articles on U.S. regionals, S&Ls. $PNC, $FITB, and $BHLB are top picks